Aldosterone blockade in CKD: emphasis on pharmacology

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Endocrinology

Background:

• Aldosterone promotes inflammation and fibrosis in the heart, kidneys, and blood vessels.
• Elevated aldosterone levels are observed in chronic kidney disease (CKD), often disproportionate to fluid status.
• Paradoxical aldosterone increases occur in 30-40% of CKD patients treated with renin-angiotensin system inhibitors.

Purpose of the Study:

• To explore the potential of mineralocorticoid receptor blockers in managing aldosterone-mediated inflammation and fibrosis in CKD.
• To identify key unresolved issues regarding the use of mineralocorticoid receptor blockers in CKD patients.

Main Methods:

• Review of existing literature on aldosterone's role in CKD.
• Analysis of studies investigating renin-angiotensin system inhibitors and their effect on aldosterone levels.
• Examination of the pharmacology of mineralocorticoid receptor blockers.

Main Results:

• Aldosterone has detrimental effects beyond epithelial sodium transport, contributing to organ damage in CKD.
• Current renin-angiotensin system-blocking therapies can lead to increased aldosterone levels in a significant subset of CKD patients.
• Mineralocorticoid receptor blockers present a potential therapeutic strategy targeting these aldosterone effects.

Conclusions:

• Mineralocorticoid receptor blockers are of interest for treating inflammation and fibrosis in CKD.
• Safety concerns exist for using these agents in advanced CKD and end-stage renal disease (ESRD) populations.
• Further research is needed to understand drug efficacy across diverse racial and ethnic groups and to guide clinical practice.